{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:18Z","timestamp":1794047478899,"version":"4.8.0"},"reference-count":37,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph- ALL) has significantly improved patients\u2019 prognosis. Within the Campus ALL network, we analyzed the outcome of adult Ph- ALL patients treated according to the GIMEMA LAL1913 protocol outside the clinical trial to compare the real-life data with the study results. We included 421 consecutive patients; median age 42 years. The complete remission (CR) rate after the first course of chemotherapy was 94%, and measurable residual disease (MRD) negativity after the third course was achieved in 72% of patients. The 3-year overall survival (OS) and disease-free survival (DFS) were 67% and 57%, respectively. In a multivariate analysis, MRD positivity negatively influenced DFS. In a time-dependent analysis including only very high-risk (VHR) and MRD positive cases, transplanted (hematopoietic stem cell transplantation [HSCT]) patients had a significantly better DFS than non-HSCT patients (P=0.0017). During induction, grade \u22652 pegaspargase-related hepato-toxicity was observed in 25% of patients (vs. 12% in the GIMEMA LAL1913 trial, P=0.0003). In this large, real-life cohort of Ph- ALL, we confirmed the very high CR rate and a superimposable OS and DFS compared to the GIMEMA LAL1913 clinical trial (CR rate after C1, 94% vs. 85%, P=0.0004; 3-year OS, 67% vs. 67%, P=0.94; 3-year DFS, 57% vs. 63%, P=0.17). HSCT confirms its important role in VHR and MRD-positive patients. The rate of pegaspargase-related toxicity was significantly higher in the real-life setting, emphasizing the importance of dose adjustment in the presence of risk factors to avoid excessive toxicity.<\/jats:p>","DOI":"10.3324\/haematol.2024.285638","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T18:08:27Z","timestamp":1723658907000},"page":"55-67","source":"Crossref","is-referenced-by-count":7,"title":["Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study"],"prefix":"10.3324","volume":"110","author":[{"given":"Davide","family":"Lazzarotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Chiaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mosna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fracchiolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Zappasodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Imbergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ilaria","family":"Del Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Lussana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelina","family":"Dargenio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prassede","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Forghieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Giulia","family":"Da Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Olivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Trappolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Leoncin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Delia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crescenza","family":"Pasciolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Cambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Guolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Minetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Defina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endri","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Trastulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Bellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Della","family":"Starza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicetto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pizzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Foa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"70727","doi-asserted-by":"crossref","unstructured":"Bassan R, Chiaretti S, Della Starza I. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023; 7(16):4448-4461.","DOI":"10.1182\/bloodadvances.2022009596"},{"key":"70728","doi-asserted-by":"crossref","unstructured":"Bassan R, Pavoni C, Intermesoli T. Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10\/07. Blood Cancer J. 2020; 10(11):119.","DOI":"10.1038\/s41408-020-00383-2"},{"key":"70729","doi-asserted-by":"crossref","unstructured":"Huguet F, Leguay T, Raffoux E. Pediatric-inspired therapy in adults with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27(6):911-918.","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"70730","doi-asserted-by":"crossref","unstructured":"Huguet F, Chevret S, Leguay T. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol. 2018; 36(24):2514-2523.","DOI":"10.1200\/JCO.2017.76.8192"},{"key":"70731","doi-asserted-by":"crossref","unstructured":"Toft N, Birgens H, Abrahamsson J. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018; 32(3):606-615.","DOI":"10.1038\/leu.2017.265"},{"key":"70732","doi-asserted-by":"crossref","unstructured":"Stock W, Luger SM, Advani AS. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019; 133(14):1548-1559.","DOI":"10.1182\/blood-2018-10-881961"},{"key":"70733","doi-asserted-by":"crossref","unstructured":"Testi AM, Canichella M, Vitale A. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial. Am J Hematol. 2021; 96(3):292-301.","DOI":"10.1002\/ajh.26066"},{"key":"70734","doi-asserted-by":"crossref","unstructured":"Siegel SE, Stock W, Johnson RH. Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review. JAMA Oncol. 2018; 4(5):725-734.","DOI":"10.1001\/jamaoncol.2017.5305"},{"key":"70735","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S. Diagnosis, prognostic factors and assessment of ALL in adults: 2023 ELN recommendations from a European expert panel. Blood. 2024; 143(19):1891-1902.","DOI":"10.1182\/blood.2023020794"},{"key":"70736","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S. Management of ALL in adults: 2023 ELN recommendations from a European expert panel. Blood. 2024; 143(19):1903-1930.","DOI":"10.1182\/blood.2023023568"},{"key":"70737","doi-asserted-by":"crossref","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007; 21(4):604-611.","DOI":"10.1038\/sj.leu.2404586"},{"key":"70738","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N. How I treat older patients with ALL. Blood. 2013; 122(8):1366-1375.","DOI":"10.1182\/blood-2012-07-379016"},{"key":"70739","doi-asserted-by":"crossref","unstructured":"Hanbali A, Kotb A, Fakih RE. Improved survival in adolescents and young adults (AYA) patients aged 14-55 years with acute lymphoblastic leukemia using pediatric-inspired protocol - a retrospective analysis of a real-world experience in 79 of patients treated at a national tertiary care referral center. Leuk Res Rep. 2021; 16:100270.","DOI":"10.1016\/j.lrr.2021.100270"},{"key":"70740","doi-asserted-by":"crossref","unstructured":"Ferrari LC, Rivas MM, Navickas AB. PH negative acute lymphoblastic leukemia in adolescents and young adults treated according to a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients. Ann Hematol. 2023; 102(5):1087-1097.","DOI":"10.1007\/s00277-023-05151-3"},{"key":"70741","doi-asserted-by":"crossref","unstructured":"Reed DR, Wooster M, Isom S. Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen. Ann Hematol. 2023; 102(4):897-906.","DOI":"10.1007\/s00277-023-05141-5"},{"key":"70742","doi-asserted-by":"crossref","unstructured":"Oravcova I, Lukas J, Cingelova S. Treatment of adults and young adults with acute lymphoblastic leukemia: real life data from two centers in Slovakia. Clin Lymphoma Myeloma Leuk. 2021; 21(10):e782-e791.","DOI":"10.1016\/j.clml.2021.06.009"},{"key":"70743","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Kneba M, Raff T. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012; 120(9):1868-1876.","DOI":"10.1182\/blood-2011-09-377713"},{"key":"70744","doi-asserted-by":"crossref","unstructured":"Beldjord K, Chevret S, Asnafi V. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014; 123(24):3739-3749.","DOI":"10.1182\/blood-2014-01-547695"},{"key":"70745","doi-asserted-by":"crossref","unstructured":"Dh\u00e9din N, Huynh A, Maury S. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015; 125(16):2486-2496.","DOI":"10.1182\/blood-2014-09-599894"},{"key":"70746","unstructured":"Bassan R, Chiaretti S, Della Starza I. Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial for newly diagnosed adult Ph-negative B-lineage ALL patients. Hemasphere. 2021; 5(8):S114."},{"key":"70747","doi-asserted-by":"crossref","unstructured":"Ribera JM, Morgades M, Ciudad J. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021; 137(14):1879-1894.","DOI":"10.1182\/blood.2020007311"},{"key":"70748","doi-asserted-by":"crossref","unstructured":"Stock W, Douer D, DeAngelo DJ. Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011; 52(12):2237-2253.","DOI":"10.3109\/10428194.2011.596963"},{"key":"70749","doi-asserted-by":"crossref","unstructured":"Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. Blood. 2020; 135(13):987-995.","DOI":"10.1182\/blood.2019002477"},{"key":"70750","doi-asserted-by":"crossref","unstructured":"Mariette C, Tavernier E, Hocquet D. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leuk Lymphoma. 2017; 58(3):586-593.","DOI":"10.1080\/10428194.2016.1204652"},{"key":"70751","doi-asserted-by":"crossref","unstructured":"Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2016; 101(4):407-416.","DOI":"10.3324\/haematol.2015.141101"},{"key":"70752","doi-asserted-by":"crossref","unstructured":"Paietta E, Roberts KG, Wang V. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood. 2021; 138(11):948-958.","DOI":"10.1182\/blood.2020010144"},{"key":"70753","doi-asserted-by":"crossref","unstructured":"Moorman AV, Barretta E, Butler ER. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia. 2022; 36(3):625-636.","DOI":"10.1038\/s41375-021-01448-2"},{"key":"70754","doi-asserted-by":"crossref","unstructured":"Chiaretti S, Messina M, Fo\u00e0 R. BCR\/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat?. Cancer. 2019; 125(2):194-204.","DOI":"10.1002\/cncr.31848"},{"key":"70755","doi-asserted-by":"crossref","unstructured":"Boissel N, Huguet F, Leguay T. Blinatumomab during consolidation in high-risk Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) adult patients: a two-cohort comparison within the Graall-2014\/B study. Blood. 2022; 140(Suppl 1):507-509.","DOI":"10.1182\/blood-2022-159397"},{"key":"70756","doi-asserted-by":"crossref","unstructured":"Litzow MR, Sun Z, Paietta E. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network trial. Blood. 2022; 140(Suppl 2):LBA-1.","DOI":"10.1182\/blood-2022-171751"},{"key":"70757","doi-asserted-by":"crossref","unstructured":"Lussana F, Minetto P, Ferrara F, Chiaretti S, Specchia G, Bassan R. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. BMC Cancer. 2020; 20(1):956.","DOI":"10.1186\/s12885-020-07461-5"},{"key":"70758","doi-asserted-by":"crossref","unstructured":"Derman BA, Streck M, Wynne J. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020; 61(3):614-622.","DOI":"10.1080\/10428194.2019.1680839"},{"key":"70759","doi-asserted-by":"crossref","unstructured":"Schore RJ, Devidas M, Bleyer A. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children\u2019s Oncology Group AALL07P4. Leuk Lymphoma. 2019; 60(7):1740-1748.","DOI":"10.1080\/10428194.2018.1542146"},{"key":"70760","doi-asserted-by":"crossref","unstructured":"Keng MB, Keng HC, Tan BH, Wong GC. High risk of invasive fungal infections in adult acute lymphoblastic leukemia patients receiving induction and salvage chemotherapy. Leuk Lymphoma. 2017; 58(8):2017-2018.","DOI":"10.1080\/10428194.2016.1267351"},{"key":"70761","doi-asserted-by":"crossref","unstructured":"Luskin MR. Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?. Hematology Am Soc Hematol Educ Program. 2021; 2021(1):7-14.","DOI":"10.1182\/hematology.2021000226"},{"key":"70762","doi-asserted-by":"crossref","unstructured":"Stelljes M, Raffel S, Alakel N. Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL. J Clin Oncol. 2024; 42(3):273-282.","DOI":"10.1200\/JCO.23.00546"},{"key":"70763","doi-asserted-by":"crossref","unstructured":"Goekbuget N, Schwartz S, Faul C. Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph\/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL Bold trial. Blood. 2023; 142(Suppl 1):964.","DOI":"10.1182\/blood-2023-180472"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285638\/77467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285638\/77939","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11729\/77467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:09Z","timestamp":1794046029000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285638","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}